Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Nerispirdine
HP184 · 3 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| Nerispirdine 50mg | EXPERIMENTAL | Nerispirdine 50mg once daily for 14 weeks |
| Nerispirdine 100mg | EXPERIMENTAL | Nerispirdine 100mg once daily for 14 weeks |
| Nerispirdine 200mg | EXPERIMENTAL | Nerispirdine 200mg once daily for 14 weeks |
| Placebo | PLACEBO_COMPARATOR | Placebo for Nerispirdine once daily for 14 weeks |
| Sequence 1 | EXPERIMENTAL | placebo,1 day treatment period 1 50 mg Nerispirdine, 1 day treatment period 2 400 mg Nerispirdine, 1 day treatment period 3 |
| Sequence 2 | EXPERIMENTAL | placebo,1 day treatment period 1 400 mg Nerispirdine, 1 day treatment period 2 50 mg Nerispirdine, 1 day treatment period 3 |
| Sequence 3 | EXPERIMENTAL | 50 mg Nerispirdine, 1 day treatment period 1 placebo, 1 day treatment period 2 400 mg Nerispirdine, 1 day treatment period 3 |
| Sequence 4 | EXPERIMENTAL | 50 mg Nerispirdine, 1 day treatment period 1 400 mg Nerispirdine, 1 day treatment period 2 placebo, 1 day treatment period 3 |
| Sequence 5 | EXPERIMENTAL | 400 mg Nerispirdine, 1 day treatment period 1 placebo, 1 day treatment period 2 50 mg Nerispirdine, 1 day treatment period 3 |
| Sequence 6 | EXPERIMENTAL | 400 mg Nerispirdine, 1 day treatment period 1 50 mg Nerispirdine, 1 day treatment period 2 placebo, 1 day treatment period 3 |
| Name | Type | Description |
|---|---|---|
| Nerispirdine | DRUG | tablet, oral administration |
| placebo | DRUG | tablet, oral administration |
| HP184 | DRUG | - |
Inclusion Criteria: * Clinically definite MS (according to McDonald criteria), Exclusion Criteria: * Multiple sclerosis exacerbation or clinical relapse within 6-month prior to the screening visit. * Subject who is not able to complete two trials of a timed 25 foot walk, with or without an assist...
HP184 is an investigational small molecule being developed for the treatment of spinal cord injury. It is intended for patients with chronic spinal cord injury, a neurological condition that can result in loss of motor and sensory function. The drug is currently in clinical development, having completed a Phase 2 trial.
HP184 is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol SNY. Sanofi is responsible for the research and clinical development of this investigational drug for spinal cord injury.
HP184 is in Phase 2 of clinical development. A Phase 2 trial has been completed, but the drug is not yet approved and remains investigational. It is still in the clinical research stage, and further studies may be needed to establish its safety and efficacy.
HP184 has one completed clinical trial registered under the identifier NCT00093275. This Phase 2 study, titled 'HP184 in Chronic Spinal Cord Injury Subjects,' enrolled 262 participants across the United States, Australia, Germany, India, and the United Kingdom. The trial was randomized and double-blind.
HP184 is not FDA approved. It is an investigational drug that has completed a Phase 2 clinical trial for spinal cord injury. The drug is still in clinical development, and its safety and efficacy have not been fully established. Regulatory approval has not been granted.